Literature DB >> 6806087

Stuporous episodes during treatment with sodium valproate: report of seven cases.

C Marescaux, J M Warter, G Micheletti, L Rumbach, G Coquillat, D Kurtz.   

Abstract

Of 13 patients with complex partial seizures who experienced stuporous states during treatment with sodium valproate (VPA), 4 received VPA only, 4 VPA and phenobarbital (PB) and 5 VPA, PB, and a third anticonvulsant. Seven cases were described in detail. Side effects-stupor or confusion-appeared a few days after efficacious drug plasma levels were attained, persisted until therapy was readjusted, and disappeared 24 to 72 h after VPA withdrawal. Therapeutic trials established the role of VPA in the onset of stuporous states. The adverse effects of VPA were potentiated by the concomitant administration of other anticonvulsants. Stupor was not due to VPA overdoses, and plasma concentration of the drugs were not correlated with the electroclinical signs. The EEG showed spike and wave discharges or continuous sharp theta and delta waves persisting during VPA treatment. The fact that all 13 stuporous, VPA-treated patients were subjected to partial seizures with complex symptomatology, and none were cases of generalized epilepsy, together with the observations that the disturbances of consciousness started with focal symptoms and EEG signs resembling those of spontaneously occurring partial seizures, suggest that VPA given alone or in association with other antiepileptics has a paradoxical epileptogenic effect in certain forms of epilepsy.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6806087     DOI: 10.1111/j.1528-1157.1982.tb06195.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  12 in total

1.  Valproic acid-associated encephalopathy.

Authors:  G L Jones; F Matsuo; J R Baringer; W H Reichert
Journal:  West J Med       Date:  1990-08

2.  Hyperammonaemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs.

Authors:  R N Ratnaike; G J Schapel; G Purdie; R H Rischbieth; S Hoffmann
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

Review 3.  The risk-benefit ratio of anticonvulsant drugs.

Authors:  M J Eadie
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Sep-Oct

4.  Unilateral basal-ganglia involvement likely due to valproate-induced hyperammonemic encephalopathy.

Authors:  Swarnali Joardar; Shubhadeep Das; Rita Chatterjee; Gautam Guha; M A Hasmi
Journal:  Neurol Sci       Date:  2011-11-16       Impact factor: 3.307

5.  Lack of relationship between sodium valproate-induced adverse effects and the plasma concentration of its metabolite 2-propylpenten-4-oic acid.

Authors:  M Paganini; G Zaccara; F Moroni; R Campostrini; L Bendoni; G Arnetoli; R Zappoli
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 6.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

7.  State of stupor from valproic acid during chronic treatment: case report.

Authors:  S Gentile; C Buffa; C Ravetti; I Sacerdote
Journal:  Ital J Neurol Sci       Date:  1991-04

8.  Sodium valproate "encephalopathy": report of three cases with generalised epilepsy.

Authors:  A Tartara; R Manni
Journal:  Ital J Neurol Sci       Date:  1985-03

Review 9.  Clinical pharmacokinetics of valproic acid--1988.

Authors:  G Zaccara; A Messori; F Moroni
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

Review 10.  Antiepileptic drug-induced pharmacodynamic aggravation of seizures: does valproate have a lower potential?

Authors:  Edouard Hirsch; Pierre Genton
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.